COMP <GO>
BEAM vs RXRX // GROSS PROFIT MARGIN
Beam Therapeutics Inc. (NASDAQ) VS. Recursion Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: BEAM 7
— RXRX 1
■ METRIC PARITY
LAST: $25.87 (-4.99%) • MKT CAP: $2.67B
gross-margins
—
LAST: $3.83 (-4.96%) • MKT CAP: $2.29B
gross-margins
5.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BEAM VS. RXRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BEAM | RXRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | 5.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.10% | -35.00% | +2.90 | BEAM | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -12.09% | -14.95% | +2.86 | BEAM | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -57.20% | -60.00% | +2.80 | BEAM | /net-margins <GO> |
| Revenue Growth (YoY) | 120.00% | 26.90% | +93.10 | BEAM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.00 | 1.59 | +4.41 | BEAM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | RXRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.1 | 47.8 | +2.30 | BEAM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.00 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 32.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.67B | $2.29B | $386.0M | BEAM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BEAM REV | RXRX REV | BEAM GROSS % | RXRX GROSS % | BEAM FCF | RXRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $139.7M | $74.7M | — | 5.0% | -$360.0M | -$378.3M |
| FY 2024 | $63.5M | $58.8M | — | 23.1% | -$356.2M | -$372.9M |
| FY 2023 | $377.7M | $44.6M | — | — | -$149.2M | -$289.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BEAM // BETA —
RXRX // BETA 1.00